| TOTAL: $217.67M | |||
| Year to Date: $754.98M | |||
| Company (Symbol)#* | Partner (Country) | Amt. (M) | Details (Date) |
| Ablynx NV (Belgium;BR:ABLX) | Boehringer Ingelheim GmbH (Germany) | €3 ($4.4) | As part of the 2007 collaboration focused on the development and commercialization of nanobodies (10/1) |
| Ablynx NV (Belgium; BR:ABLX) | Novartis AG (Switzerland) | ND | For an exclusive research license for one of the programs included in their ongoing R&D alliance focused on discovering nanobodies against targets that are difficult to address with conventional antibodies and fragments (10/5) |
| Affiris AG* (Austria) | GlaxoSmithKline plc (UK) | €10($14.92) | For Phase I studies of two Alzheimer's vaccines, AD01 and AD02, meeting their primary endpoints (10/20) |
| Depomed Inc. (DEPO) | Covidien Inc. (Ireland; NYSE:COV) | $0.5 | For the delivery of the first formulation under a worldwide license agreement focused on the development of four products using Depomed's Acuform gastric retentive drug delivery technology (10/22) |
| Evotec AG (Germany; FSE:EVT) | Cardioxyl Pharmaceuticals Inc.* | ND | For CXL-1020 moving into Phase I/IIa testing in heart failure patients (10/1) |
| Evotec AG (Germany; FSE:EVT) | Boehringer Ingelheim GmbH (Germany) | €2.5 ($3.75) | For the selection of a candidate compound for predevelopment studies in a cardiometabolic program (10/22) |
| Genmab A/S (Denmark; CSE:GEN) | GlaxoSmithKline plc (UK) | DKK116($23.1) | For the FDA approval of Arzerra to treat chronic lymphocytic leukemia (10/27) |
| Halozyme Therapeutics Inc. (HALO) | F. Hoffmann-La Roche Ltd. (Switzerland) | $5 | For the start of a Phase III trial of subcutaneous Herceptin (10/22) |
| Human Genome Sciences Inc. (HGSI) | Novartis AG (Switzerland) | $75 | For the successful completion of the Phase III development of Zalbin to treat chronic hepatitis C and the decision to file for regulatory approval (10/19) |
| Odyssey Thera Inc.* | Pfizer Inc. | ND | For the advancement of specific drug candidates under an August 2006 multiyear alliance (10/7) |
| Psynova Neurotech Ltd.* (UK) | Rules-Based Medicine Inc.* | ND | For the discovery and characterization of a combination of protein biomarkers demonstrating use as an adjunctive aid in the differential diagnosis of schizophrenia (10/20) |
| Scynexis Inc.* | Merck & Co. Inc. | ND | For achieving a preclinical milestone resulting from a collaboration to discover and develop novel oncology agents (10/27) |
| Soligenix Inc. (OTC BB:SNGX; formerly DOR Biopharma Inc.) | Sigma-Tau Pharmaceuticals Inc. | $1 | For the start of a confirmatory Phase III trial of orBec in acute gastrointestinal graft-vs.-host disease (10/15) |
| Theravance Inc. (THRX) | Astellas Pharma US Inc. | $20 | For the approval of Vibativ (telavancin) in September and for supplying Astellas with launch inventory for U.S. sales (10/23) |
| ZymoGenetics Inc. (ZGEN) | Bristol-Myers Squibb Co. | $70 | For the start of a Phase II trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naive patients with chronic hepatitis C virus infection (10/27) |
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. * Private company. Currency conversions are based on exchange rates at the time of the deal.ND = Not disclosed. BR = Brussels Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
